Cigna Invests In GNS Healthcare Precision Medicine Venture
Summary
GNS said Tuesday it has raised $23 million led by Cigna Ventures as the health insurer looks to more precisely “match therapeutics, procedures and care management interventions to individuals to drive personalized clinical care,” GNS and Cigna said in a statement. The Cigna investment fits the effort by health insurance companies to use claims data and related patient health information to better target illness and provide more cost-effective and high quality patient care. “GNS aligns with our vision and together we can super-charge our advanced analytics capabilities and provide even deeper, more predictable insights that will further enhance customer access to the highest quality treatment and care, in the preferred and appropriate place, at the right time,” Tom Richards, Cigna’s global lead, strategy business development said in a statement accompanying the announcement about the GNS investment. Prior to the latest investment led by Cigna and announced Tuesday, GNS had raised $38 million from several investors including Celgene and Amgen Ventures, the venture arm of the drug maker Amgen. “As one of the largest and most forward-thinking global health services companies, Cigna is the perfect complement to our cadre of leading biopharma companies and health plan partners committed to improving patient outcomes through causal AI and the precision healthcare it enables,” GNS Healthcare’s chairman, chief executive and co-founder, Colin Hill said.
Classifications
AskAI Classifications
LabelsLinked Companies
